     AV-299AV-299 AV-299 is the first product candidate from AVEO’s antibody drug discovery engine to enter clinical development. AV-299 is a high-affinity monoclonal antibody whose binding to Hepatocyte Growth Factor / Scatter Factor (HGF/SF) potently neutralizes the biological activities of HGF in vitro and in vivo. The HGF/c-Met pathway is frequently deregulated in different types of human cancers and is thought to play an important role in regulating tumor growth, invasion and metastasis. In collaboration with Schering-Plough, AV-299 is in Phase 1 development in patients with relapsed or refractory tumors or lymphoma. Under this exclusive worldwide license and development agreement with Schering-Plough (announced April 4, 2007), AVEO has primary responsibility for clinical development of AV-299 through Phase 2 proof-of-concept in man, and retains co-promotion rights in the U.S. for certain oncology indications. AVEO is applying its Human Response Platform (HRP™) during a multi-year translational research program designed to discover biomarker profiles of patients most likely to benefit from treatment with AV-299. Using its proprietary preclinical models of human cancer, AVEO can identify specific populations of tumors in which the HGF/c-Met pathway plays a critical role in tumor maintenance, as opposed to those in which the pathway is activated but not essential. Its HRP technology provides AVEO with unique insight into the biology of anti-HGF therapies, and uniquely positions it to guide AV-299 through clinical development. AVEO’s AV-299 program exemplifies the progress AVEO has made in discovering drugs that target functionally-relevant tumor maintenance genes identified and validated by AVEO in its proprietary in vivo cancer models. AVEO advanced this antibody from discovery to the clinic in only three years.
|
|
 |
|
